Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03341754 · ClinicalTrials.gov registry record · Phase 1
Trial to Evaluate the Safety, Immunogenicity, and Efficacy of Malaria Infection in Malaria Naïve Adults
A Phase 1 study, sponsored by U.S. Army Medical Research and Development Command.
- Completed
- Registry status
- Phase 1
- Development phase
- 52
- Enrollment target
NCT03341754 is a Phase 1 study that has completed, run by U.S. Army Medical Research and Development Command. The registered enrollment target is 52 participants.
The verdict
NCT03341754, a Phase 1 study, has completed, sponsored by U.S. Army Medical Research and Development Command.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 52 participants
- Enrollment target
Study Summary
This is a study designed to assess the safety, tolerability, immunogenicity, and protective efficacy of 2 heterologous prime-boost vaccine regimens in healthy, malaria naïve adults. The study will include 2 vaccine groups and an infectivity control (IC) group consisting of non-immunized subjects. Subjects to be immunized will be randomly assigned to one of two vaccine groups.
Interventions
- BIOLOGICAL D/ChAd63-CA
- BIOLOGICAL D/ChAd63-CAT
- OTHER Infectivity Control (IC) Group
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2018-09-15 |
| Est. Completion | 2020-03-23 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03341754
The ClinicalTrials.gov registry entry for NCT03341754 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is U.S. Army Medical Research and Development Command, which has 77 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which D/ChAd63-CA is the first listed.
NCT03341754 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03341754 about?
NCT03341754 is a clinical study titled "Trial to Evaluate the Safety, Immunogenicity, and Efficacy of Malaria Infection in Malaria Naïve Adults". This is a study designed to assess the safety, tolerability, immunogenicity, and protective efficacy of 2 heterologous prime-boost vaccine regimens in healthy, malaria naïve adults. The study will include 2 vaccine groups and an infectivity control (IC) group consisting of non-immunized subjects. Su...
What is the current status of trial NCT03341754?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 52 participants. The study started on 2018-09-15. Estimated completion is 2020-03-23.
What interventions are being tested in trial NCT03341754?
The interventions under investigation include: D/ChAd63-CA (BIOLOGICAL), D/ChAd63-CAT (BIOLOGICAL), Infectivity Control (IC) Group (OTHER).
Who is sponsoring clinical trial NCT03341754?
This trial is sponsored by U.S. Army Medical Research and Development Command, which has 77 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.